In the latest trading session, 0.39 million Nektar Therapeutics (NASDAQ:NKTR) shares changed hands as the company’s beta touched 0.65. With the company’s most recent per share price at $0.89 changed hands at -$0.04 or -4.67% at last look, the market valuation stands at $163.92M. NKTR’s current price is a discount, trading about -116.85% off its 52-week high of $1.93. The share price had its 52-week low at $0.63, which suggests the last value was 29.21% up since then.
Analysts gave the Nektar Therapeutics (NKTR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NKTR as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Nektar Therapeutics’s EPS for the current quarter is expected to be -0.19.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Instantly NKTR was in red as seen in intraday trades today. With action -9.56%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -4.45%, with the 5-day performance at -9.56% in the red. However, in the 30-day time frame, Nektar Therapeutics (NASDAQ:NKTR) is -0.67% down.
The consensus price target for the stock as assigned by Wall Street analysts is 18.5, meaning bulls need an upside of 95.19% from its recent market value. According to analyst projections, NKTR’s forecast low is 6 with 24 as the target high. To hit the forecast high, the stock’s price needs a -2596.63% plunge from its current level, while the stock would need to soar -574.16% for it to hit the projected low.
Nektar Therapeutics (NKTR) estimates and forecasts
Year-over-year growth is forecast to reach 17.53% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 36.65M. 6 analysts are of the opinion that Nektar Therapeutics’s revenue for the current quarter will be 22.39M. The company’s revenue for the corresponding quarters a year ago was 23.89M and 21.64M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 53.46%. The estimates for the next quarter sales put growth at 3.47%.
The 2025 estimates are for Nektar Therapeutics earnings to increase by 50.60%, but the outlook for the next 5-year period is at 21.38% per year.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.7823% or 15.16 million shares worth $18.79 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund. With 9.4 shares estimated at $8.22 million under it, the former controlled 5.10% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.10% of the shares, roughly 5.72 shares worth around $5.01 million.
